Optimizing treatment of hepatic metastases from colorectal cancer: Resection or resection plus ablation?

Research output: Contribution to journalArticle

Abstract

The present study determines the oncologic outcome of the combined resection and ablation strategy for colorectal liver metastases (CRLM). Between January 1994 and December 2014, 360 patients underwent surgery for CRLM. There were 280 patients who underwent hepatic resection only (group 1) and 80 hepatic resection plus ablation (group 2). group 2 patients had a higher incidence of multiple metastases than group 1 cases (100% in group 2 vs. 28.2% in group 1; P

Original languageEnglish
Pages (from-to)1280-1289
Number of pages10
JournalInternational Journal of Oncology
Volume48
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Liver
Colorectal Surgery
Therapeutics
Incidence

Keywords

  • Colorectal cancer
  • Cryosurgical ablation
  • Hepatic metastases
  • Liver resection
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{d4d53ed95b3d473898b4653f479e3a0d,
title = "Optimizing treatment of hepatic metastases from colorectal cancer: Resection or resection plus ablation?",
abstract = "The present study determines the oncologic outcome of the combined resection and ablation strategy for colorectal liver metastases (CRLM). Between January 1994 and December 2014, 360 patients underwent surgery for CRLM. There were 280 patients who underwent hepatic resection only (group 1) and 80 hepatic resection plus ablation (group 2). group 2 patients had a higher incidence of multiple metastases than group 1 cases (100{\%} in group 2 vs. 28.2{\%} in group 1; P",
keywords = "Colorectal cancer, Cryosurgical ablation, Hepatic metastases, Liver resection, Radiofrequency ablation",
author = "Antonio Chiappa and Emilio Bertani and Zbar, {Andrew P.} and Diego Foschi and Nicola Fazio and Zampino, {Maria Giulia} and Claudio Belluco and Franco Orsi and {Della Vigna}, Paolo and Guido Bonomo and Marco Venturino and Carlo Ferrari and Roberto Biffi",
year = "2016",
month = "3",
day = "1",
doi = "10.3892/ijo.2016.3324",
language = "English",
volume = "48",
pages = "1280--1289",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Optimizing treatment of hepatic metastases from colorectal cancer

T2 - Resection or resection plus ablation?

AU - Chiappa, Antonio

AU - Bertani, Emilio

AU - Zbar, Andrew P.

AU - Foschi, Diego

AU - Fazio, Nicola

AU - Zampino, Maria Giulia

AU - Belluco, Claudio

AU - Orsi, Franco

AU - Della Vigna, Paolo

AU - Bonomo, Guido

AU - Venturino, Marco

AU - Ferrari, Carlo

AU - Biffi, Roberto

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The present study determines the oncologic outcome of the combined resection and ablation strategy for colorectal liver metastases (CRLM). Between January 1994 and December 2014, 360 patients underwent surgery for CRLM. There were 280 patients who underwent hepatic resection only (group 1) and 80 hepatic resection plus ablation (group 2). group 2 patients had a higher incidence of multiple metastases than group 1 cases (100% in group 2 vs. 28.2% in group 1; P

AB - The present study determines the oncologic outcome of the combined resection and ablation strategy for colorectal liver metastases (CRLM). Between January 1994 and December 2014, 360 patients underwent surgery for CRLM. There were 280 patients who underwent hepatic resection only (group 1) and 80 hepatic resection plus ablation (group 2). group 2 patients had a higher incidence of multiple metastases than group 1 cases (100% in group 2 vs. 28.2% in group 1; P

KW - Colorectal cancer

KW - Cryosurgical ablation

KW - Hepatic metastases

KW - Liver resection

KW - Radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=84958999170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958999170&partnerID=8YFLogxK

U2 - 10.3892/ijo.2016.3324

DO - 10.3892/ijo.2016.3324

M3 - Article

VL - 48

SP - 1280

EP - 1289

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -